The drug will be effective against swine flu, the Izvestia newspaper reported. 

“It will be effective against both swine flu and other strains,” Alexander Gintsburg, director of the Gamaleya Center, was quoted as saying. 

According to the developer of the drug, Doctor of Biological Sciences Maxim Shmarov, the design features of the nasal vaccine are such that protection will be formed against different strains of influenza A. It will also protect against types of influenza type B. 

Sharov added that the nasal vaccine is able to induce long-term protection, so annual vaccination will not be needed. Such drugs contribute to the formation of active immune protection on the mucous membrane of the human upper respiratory tract, as well as to form a barrier that stops viruses. 

Currently, vaccine trials have already shown successful results. Now scientists will prepare for the next stage of testing, which is scheduled to be completed in 2023.